Please Wait
Applying Filters...
menu
    • menu
    Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.

    Virtual Booth

    Contact Supplier

    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    TAPI, a leading global supplier of APIs, provides over 350 products and customized CDMO solutions for every stage of development.

    Virtual Booth

    Contact Supplier

    Boai NKY Pharmaceuticals Ltd. is one of the largest global PVP suppliers.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2025-06-09

    Virtual Booth

    An Enquiry

    Left Arrow
    Right Arrow

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Established by Prof. Raymond Kaempfer and Dr. Gila Arad from the faculty of medicine at the Hebrew University, Atox Bio is a late stage biotechnology company that develops novel immunomodulators for critically ill patients. Reltecimod, Atox Bio’s lead product, is initially being developed to treat Necrotizing Soft Tissue Infections (NSTI), a rare, life threatening infection for which no therapy currently exists. Atox Bio r...
    Established by Prof. Raymond Kaempfer and Dr. Gila Arad from the faculty of medicine at the Hebrew University, Atox Bio is a late stage biotechnology company that develops novel immunomodulators for critically ill patients. Reltecimod, Atox Bio’s lead product, is initially being developed to treat Necrotizing Soft Tissue Infections (NSTI), a rare, life threatening infection for which no therapy currently exists. Atox Bio recently completed enrollment of the ACCUTE (Reltecimod Clinical Composite endpoint Study in necrotizing soft Tissue InfEctions) study, a phase 3 clinical trial evaluating the efficacy of Reltecimod in patients with NSTI.

    List your booth number for exhibitions, ask us